Influence of Genetic Variants in TPMT and COMT Associated with Cisplatin Induced Hearing Loss in Patients with Cancer: Two New Cohorts and a Meta-Analysis Reveal Significant Heterogeneity between Cohorts

Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer

(2014) Andrey V Khrunin et al.   PHARMACOGENOMICS

The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin-Induced Ototoxicity in Children With Cancer

(2013) J J Yang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children

(2013) K Pussegoda et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

On Variability and Genes: Inter-individual Differences in Auditory Brain Function

(2012) Peter Sörös et al.   Frontiers in Human Neuroscience

Platinum-Induced Ototoxicity in Children: A Consensus Review on Mechanisms, Predisposition, and Protection, Including a New International Society of Pediatric Oncology Boston Ototoxicity Scale

(2012) Penelope R. Brock et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients

(2012) Allison Yancey et al.   PEDIATRIC BLOOD & CANCER

Taqman genotyping assays can be used on decalcified and paraffin-embedded tissue from patients with osteosarcoma

(2010) Melanie M. Hagleitner et al.   PEDIATRIC BLOOD & CANCER

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy

(2009) Colin J D Ross et al.   NATURE GENETICS

The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear

(2007) J R García-Berrocal et al.   BRITISH JOURNAL OF PHARMACOLOGY